Adanma Ayanambakkam, MD, MS, discusses safety data with darlifarnib plus cabozantinib in RCC.
Adanma Ayanambakkam, MD, MS
Advertisement
Adanma Ayanambakkam, MD, MS, is the associate program director of the Hematology Oncology Fellowship & Director of Infusion Services at Stephenson Cancer Center at the University of Oklahoma Health Sciences Center.
Articles by Adanma Ayanambakkam, MD, MS
Adanma Ayanambakkam, MD, MS, discusses the design of the phase 1a FIT-001 trial of darlifarnib plus cabozantinib in RCC.
Adanma Ayanambakkam, MD, MS, discusses the background of the phase 1a FIT-001 trial of darlifarnib plus cabozantinib in RCC.
Adanma Ayanambakkam, MD, MS, discusses the safety profile of darlifarnib plus cabozantinib in ccRCC.
Adanma Ayanambakkam, MD, MS, discusses efficacy data from the phase 1a/1b FIT-001 trial.
Adanma Ayanambakkam, MD, MS, discusses the mechanism of action of darlifarnib in ccRCC.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
3
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
4
Dr Voorhees on Eligibility Criteria for the CERVINO Trial in Multiple Myeloma
5